Contact Us

Medtronic Infuse Bone-Growth
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

Date when device was implanted :

Please describe any problems or injuries caused by the product:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Medtronic Infuse Bone Growth Cancer

Medtronic Infuse Bone-Growth Cancer Side Effects Lawsuit

Facebook Twitter Stumble AddThis Social Bookmark Button Pin It Email to Friend Print Page

Medtronic Infuse Bone-Growth Lawsuit, Side Effects Cancer Risk

Medtronic Infuse Bone-Growth | rhBMP-2, Bio-Engineered Bone GrowthProtein | Lawsuits, Lawyer | Side Effects : Cancer, Stomach Cancer, Thyroid Cancer, Breast Cancer, Skin Cancer (melanoma), Ovarian Cancer, Lung Cancer, Leukemia Cancer, Prostate Cancer, Laryngeal Cancer, Lymphoma Cancer, Pancreatic Cancer, Sterility in Men, Infections, Bone Dissolution, Worsened Back, Leg Pain | Spinal Fusion Procedures, Bone Growth Product, Medtronic Amplify

Medtronic Infuse Bone-Growth Lawsuit, Side Effects Cancer Risk

An unprecedented medical journal review of Infuse found unreported complications and undisclosed financial conflicts among doctors. The complications range from sterilization in men to unwanted bone growth.

Medtronic Inc's Infuse bone graft, a bioengineered bone-growth product used in spinal surgery, has been linked to a greater cancer risk than previously thought in patients treated with high doses of Medtronic's controversial protein. People who received Infuse, especially in off-label procedures, may be at higher risk for stomach, thyroid, breast, skin (melanoma), ovarian, lung, leukemia, prostate, laryngeal, lymphoma, and pancreatic cancers. Amplify, another Medtronic product that contained a higher dose of rhBMP-2, the bio-engineered bone growth protein found in Infuse, was rejected by U.S. regulators because of its association with cancer. However, it is known that off-label Infuse procedures often require doses of rhBMP-2 that are even higher than what was present in Amplify.

Parker Waichman LLP's defective drug lawyers are actively investigating potential lawsuits on behalf of anyone who developed cancer after treatment with Medtronic Infuse. If you or someone you love was diagnosed with stomach, thyroid, breast, skin (melanoma), ovarian, lung, leukemia, prostate, laryngeal, lymphoma, or pancreatic cancer following surgery with Medtronic Infuse, you may be entitled to compensation through a lawsuit. Parker Waichman LLP offers free lawsuit evaluations to possible Medtronic Infuse cancer victims. We urge you to contact one of our experienced attorneys today to discuss your potential Medtronic Infuse cancer lawsuit by completing the form at right or calling us at 1-800-YOURLAWYER (1-800-968-7529) for a FREE Lawsuit evaluation.


Medtronic Infuse, Amplify Bone Growth Products and Cancer

Medtronic Infuse, Amplify Bone Growth Products and Cancer

Linked to a greater risk of cancer than previously thought

In March 2011, the U.S. Food & Drug Administration (FDA) rejected Medtronic's approval application for the Amplify bone graft product because of concerns it could increase cancer risks among patients who received it. The FDA Amplify decision came after Medtronic trial results showed a significantly higher number of cancers in the study group that received Amplify when compared to a control group that received a bone graft as part of a spinal fusion.

In November 2011, during a meeting of the North American Spine Society (NASS), Dr. Eugene J. Carragee of Stanford University revealed that not all the findings of that Medtronic-sponsored clinical trial had been made public. In an interview with The New York Times, Dr. Carragee said the Amplify study findings had potential implications for patients who received Infuse, as doctors often administered Infuse off-label at doses equal to or higher than Amplify.

According to Dr. Carragee, his research reflected a 2.5 times greater risk of developing cancer one year after rhBMP-2 was used and a five times greater risk after three years. He said Infuse was linked to a cancer diagnosis more often than when the product was not used at all. Amplify was tied to more cancer risk than Infuse.

Dr. Carragee was also the author of a June 2011 Spine Journal article that found that Medtronic-paid surgeons had failed to report serious complications from Infuse, including cancer, sterility in men, infections, bone dissolution and worsened back and leg pain. The article said complications occurred in 10 to 50 percent of patients who got the product in 13 Medtronic-funded clinical trials between 2000 and 2010.

Medtronic Infuse Off-Label Use

Medtronic Infuse Off-Label Use

Medtronic Bone Graft Device

Medtronic's Infuse product is approved for use in a type of spine surgery called anterior approach lumbar fusion, and two types of dental procedures. However, Infuse is widely used off-label in other spine procedures, especially cervical (neck) spine surgery, as well as in lateral approach (through the side of the body) or posterior approach (through the back of the body) spinal procedures. In July 2008, the FDA warned that Infuse bone graft and similar products had caused serious problems when they were used off-label in cervical spine (neck) surgeries. Patients reported difficulty swallowing, breathing and speaking. Several required emergency treatment, including tracheotomies and the insertion of feeding tubes, as well as second surgeries.

While doctors are not prohibited from using an approved medical product in any way they see fit, manufacturers are not legally permitted to promote or market products based on off-label uses. Even before Dr. Carragee revealed his cancer findings, the U.S. Department of Justice was investigating whether Medtronic had promoted off-label use of Infuse. The investigation was launched in November 2008, when at least 280 reports of side effects involving Infuse had been made to the FDA when the investigation. At least three quarters of those reports involved off-label use of Infuse.

Medtronic Infuse Cancer Victims - Legal Help

If you or a loved one were diagnosed with cancer following treatment with the Medtronic Infuse bone growth product, you may have valuable legal rights and may be entitled to compensation through a lawsuit. Parker Waichman LLP offers free lawsuit evaluations to possible Medtronic Infuse cancer victims. To discuss your potential Medtronic Infuse cancer lawsuit, please fill out our online lawsuit evaluation form, or call 1-800-YOURLAWYER (1-800-968-7529)  today for a FREE lawsuit evaluation.

Tags:  
Medtronic Infuse Bone Growth CancerRSS Feed

Humana Files Lawsuit Against Medtronic Over InFuse

Jun 3, 2014
Managed care company Humana Inc. has filed a lawsuit against medical device maker Medtronic, alleging the company misrepresented its Infuse bone growth product as safe and effective in spinal fusion surgeries. The suit was filed on Friday in federal court in Tennessee, and alleges that Medtronic paid for academic studies that fraudulently portrayed the product as safe and effective for uses not approved by the Food and Drug Administration (FDA), Reuters reports. Humana said it paid for...

Senate investigation details Medtronic's influence on clinical data

Dec 10, 2012
A Senate investigation has confirmed that medical device maker Medtronic Inc. paid hundreds of millions of dollars to influence clinical data on its INFUSE bone growth product. According to a Milwaukee Journal Sentinel report, the Senate Committee on Finance determined that Medtronic paid at least $210 million to a group of 13 doctors over the course of 15 years. This money and other rewards were given in exchange for favorable data used to get INFUSE approved by the Food and Drug...

Medtronic Announces Layoffs, as Infuse Controversies Drag Down Sales

Sep 28, 2012 | Parker Waichman LLP
Medtronic announced in May it would be cutting some 1,000 jobs, as the controversy surrounding its Infuse Bone Graft product continues to weigh on the medical device maker’s bottom line.  "We are eliminating about 1,000 positions around the company and around the globe," Gary Ellis, the company's chief financial officer, told the Minneapolis Star Tribune at the time. "It's kind of the normal, ongoing thing that goes forward as we shift resources from slower-growing markets to ...

Medtronic Infuse Bone Graft Lawsuit Not Preempted, Judge Rules

Aug 23, 2012 | Parker Waichman LLP
A judge has denied a motion filed by Stryker Corp. to issue a summary judgement in a lawsuit filed against it in which a woman claims the medical device company promoted its Infuse bone growth material for an off-label use to correct her previously botched back surgery.In her lawsuit, April Cabana claims she received a Medtronic bone growth product in a surgery but when that resulted in painful complications, she was then implanted with the controversial Infuse product in a procedure to correct...

Medtronic Reports Another Bad Quarter for Infuse Bone Graft

Aug 22, 2012 | Parker Waichman LLP
Medtronic Inc's spine business is still suffering as a result of all of the controversy surrounding its Infuse Bone Graft product.  According to Medtronic’s earnings report for the first quarter of 2013, sales of Infuse are down 19% from a year ago, from $174 million this time last year to $141 million.  Overall, Medtronic's core spinal business saw sales fall from $645 million in the first quarter,  from $651 million last year. Medtronic Infuse is a synthetic form of...

More Medtronic Infuse Bone Growth Cancer News

Parker Waichman Accolades And Reviews Law Dragon Best Lawyers Find Us On Avvo Protected by Copyscape Web Copyright Protection Software php-5 VendorsBay Inc